Continuous Glucose Monitoring System in Intensive Care Unit
Completed
- Conditions
- Diabetic Blood Glucose Monitoring
- Registration Number
- NCT01995994
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
To assess the accuracy, safety, and influence of sampling site of Real-time continuous glucose monitoring system (Medtronic Guardian).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Older than 18 years old
- Staying in intensive care units longer than 72 hours
Exclusion Criteria
- Skin disease
- DIC
- Immune suppressed patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference between finger stick blood glucose and real-time continuous glucose monitoring 72 hours
- Secondary Outcome Measures
Name Time Method Measurement error of real-time continuous glucose monitoring 72 hours
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie glucose fluctuations in ICU diabetic patients using Medtronic Guardian?
How does continuous glucose monitoring compare to standard blood glucose testing in ICU settings for diabetes management?
Are there specific biomarkers that predict optimal placement sites for continuous glucose monitoring in ICU patients?
What adverse events are associated with Medtronic Guardian in ICU environments and how are they managed?
What are the current alternatives to Medtronic Guardian for real-time glucose monitoring in critical care?
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital🇰🇷Seoul, Korea, Republic of